Injectable formulation for pain reduction including beta-nicotinamide mononucleotide and method of preparing the same

An injectable formulation for pain reduction upon injection, comprising:

• β-nicotinamide mononucleotide (β-NMN) at a concentration of 1 mg/mL to 1,000 mg/mL;
• and
• a hyaluronidase at a concentration of 5 IU/mL to 1,500 IU/mL;
• one or more stabilizers selected from the group consisting of mannitol, sorbitol, and lactose;
• and
• one or more alkalizing agents selected from the group consisting of sodium hydroxide (NaOH), calcium hydroxide (Ca(OH)2), and potassium hydroxide (KOH), or hydrochloric acid (HCl),
• wherein the injectable formulation has a pH of greater than 4 and less than 7, and an osmotic pressure of 800 mOsmol/kg to 1,300 mOsmol/kg.